Most Recent
Court orders have been issued barring a director of cryptocurrency exchange operator Blockchain Global from travelling outside Australia while the corporate regulator investigates the collapse of the exchange.
Trial has kicked off in ASIC's first-ever design and distribution suit over high-risk contracts for difference, after an in-principle agreement reached with investment company eToro fell through.
The judge overseeing a class action against TeleChoice has told the parties to be “prepared to spend the money” to advance the case after settlement talks stalled, saying the court is “not going to allow this to drag on”.
Andrew ‘Twiggy’ Forrest’s Fortescue can't get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.
Construction PRO
A judge wants answers on why builder Geocon has filed a $4 million construction dispute over two Canberra developments in the Federal Court, where a separate fight with its joint venture partners is playing out.
Construction PRO
A real estate agency in Victoria has lost a suit seeking the payment of its advertising costs from a former client, with a judge finding that writing 'TBA' in the contract defeated the consumer protection purpose of rules for real estate agents.
J&J-owned Janssen Pharmaceutica has sued Juno Pharmaceuticals, alleging the Australian off-patent drug maker is threatening to infringe its patent for a schizophrenia drug by seeking to list its own products on the PBS.
Private equity firm Goldstone has lost its bid to disqualify a judge from a damages hearing after he found it liable for shareholder oppression of its managing director.
A contest to run a class action against Paladin Energy played out Monday, with two law firms each positioning themselves as the better bet, one for their funding and resources, the other for their contingency fee rate.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.